Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age-Reference-Cited by-同舟云学术

Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age

Published:2001-06 Issue:3 Volume:113 Page:600-603
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Lorenzo José Ignacio,López Aurelio,Altisent Carmen,Aznar José Antonio

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2001.02828.x/fullpdf

Reference20 articles.

1. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII;Addiego;Lancet,1993

2. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group;Bray;Blood,1994

3. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products;Briët;Thrombosis and Haemostasis,1994

4. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates;De Biasi;Thrombosis and Haemostasis,1994

5. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs;Ehrenforth;Lancet,1992

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Un nouvel espoir dans le traitement de l’hémophilie A;médecine/sciences;2024-05

2. Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort study;Research and Practice in Thrombosis and Haemostasis;2023-10

3. Risk factors for coagulation inhibitor development in children with severe hemophilia A;Pediatric Hematology/Oncology and Immunopathology;2023-09-30

4. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

5. A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII;Heliyon;2023-06